Pharmaniaga Berhad

KLSE:PHARMA Rapporto sulle azioni

Cap. di mercato: RM 518.8m

Pharmaniaga Berhad Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Zulkifli Bin Jafar

Amministratore delegato

RM 168.6k

Compenso totale

Percentuale dello stipendio del CEO83.1%
Mandato del CEOless than a year
Proprietà del CEOn/a
Durata media del management1.3yrs
Durata media del Consiglio di amministrazione2.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry

Jul 18
Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry

Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S

May 09
Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S

Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Apr 19
Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Oct 03
Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Jul 19
Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Feb 18
Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Dec 10
Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

Nov 24
Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

Aug 27
We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

Pharmaniaga Berhad (KLSE:PHARMA) Has A Somewhat Strained Balance Sheet

May 28
Pharmaniaga Berhad (KLSE:PHARMA) Has A Somewhat Strained Balance Sheet

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Zulkifli Bin Jafar rispetto agli utili di Pharmaniaga Berhad?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-RM 56m

Mar 31 2024n/an/a

-RM 57m

Dec 31 2023RM 169kRM 140k

-RM 80m

Sep 30 2023n/an/a

-RM 667m

Jun 30 2023n/an/a

-RM 654m

Mar 31 2023n/an/a

-RM 655m

Dec 31 2022RM 1mRM 800k

-RM 630m

Sep 30 2022n/an/a

RM 100m

Jun 30 2022n/an/a

RM 164m

Mar 31 2022n/an/a

RM 177m

Dec 31 2021RM 145kn/a

RM 172m

Sep 30 2021n/an/a

RM 80m

Jun 30 2021n/an/a

RM 32m

Mar 31 2021n/an/a

RM 28m

Dec 31 2020RM 61kn/a

RM 27m

Compensazione vs Mercato: La retribuzione totale di Zulkifli ($USD 37.76K ) è inferiore alla media delle aziende di dimensioni simili nel mercato MY ($USD 108.35K ).

Compensazione vs guadagni: La retribuzione di Zulkifli è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Zulkifli Bin Jafar (52 yo)

less than a year

Mandato

RM 168,569

Compensazione

Encik Zulkifli Bin Jafar is the Managing Director at Pharmaniaga Berhad since September 1, 2024 and serves as its Deputy Chief Executive Officer since February 22, 2023 and was its Executive Director since...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Zulkifli Bin Jafar
Deputy CEO & Managing Directorless than a yearRM 168.57kNessun dato
Norai'ni Binti Mohamed Ali
Chief Financial Officer12.4yrsNessun datoNessun dato
Ahmad Shahredzuan Mohd Shariff
COO & Directorless than a yearRM 136.05kNessun dato
Badarulhisam Rahman
Chief Scientific Officer1.8yrsNessun datoNessun dato
Abdul Mohamed
Executive Vice President of Logistics & Distribution Divisionno dataNessun datoNessun dato
Zulhazri bin Razali
Executive Vice President of Commercial Divisionno dataNessun datoNessun dato
Wan Intan Wan Ismail
Executive VP of Corporate Governance & Company Secretary5yrsNessun datoNessun dato
Azni Basri
Chief People Officerless than a yearNessun datoNessun dato
Idham Ismail
Chief Strategy Officerno dataNessun datoNessun dato
Mohd Ishak
Acting Head of Manufacturing Operationsless than a yearNessun datoNessun dato
Fazleena Jasin
Head of Sustainabilityno dataNessun datoNessun dato
Syaruzaimi Yusof
Company Secretary5yrsNessun datoNessun dato

1.3yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di PHARMA non è considerato esperto (durata media 1.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Zulkifli Bin Jafar
Deputy CEO & Managing Directorless than a yearRM 168.57kNessun dato
Ahmad Shahredzuan Mohd Shariff
COO & Director1.8yrsRM 136.05kNessun dato
Ahmad Bakar
President Director of PT Millennium Pharmacon International Tbk4.3yrsNessun datoNessun dato
Yves Champey
Member of Board Advisory Panelno dataNessun datoNessun dato
Izaddeen Bin Daud
Non-Independent Director3.7yrsRM 192.81kNessun dato
Mohd Bin Zahur Hussain
Independent Non Executive Directorless than a yearRM 40.00kNessun dato
V. Navaratnam
Member of Board Advisory Panelno dataNessun datoNessun dato
Musa bin Mohamad
Chairman of Board Advisory Panelno dataNessun datoNessun dato
Piero Olliaro
Member of Board Advisory Panelno dataNessun datoNessun dato
Sarah binti Abdul Samat
Independent & Non-Executive Director3.3yrsRM 181.67kNessun dato
Abdul Bin Jaafar
Independent Non Executive Chairmanless than a yearNessun datoNessun dato
Abdul Bin Ahmad
Senior Independent & Non-Executive Director4yrsRM 190.04kNessun dato

2.5yrs

Durata media

52yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di PHARMA non è considerato esperto (durata media del mandato 2.5 anni), il che suggerisce un nuovo consiglio.